Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 35 min 19 sec ago

Precision NanoSystems Raises $13.4M in Series A Financing

Tue, 09/29/2015 - 15:33
VANCOUVER, British Columbia, Sept. 29, 2015 -- (Healthcare Sales & Marketing Network) -- Precision NanoSystems, Inc. (PNI), a global nanomedicine company, has announced the completion of a $13.4 million private Series A financing. The investment was led b...
Biopharmaceuticals, Venture Capital
Precision NanoSystems, nanoparticles

Corvus Pharmaceuticals Completes $75 Million Series B Financing

Tue, 09/29/2015 - 15:30
Funds Will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs BURLINGAME, Calif.--(Healthcare Sales & Marketing Network)--Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel ...
Biopharmaceuticals, Oncology, Venture Capital
Corvus Pharmaceuticals

Audentes Therapeutics Expands Senior Leadership Team

Tue, 09/29/2015 - 15:27
Natalie Holles Appointed Chief Operating Officer, Thomas Soloway Appointed Chief Financial Officer and Kevin Baker, Ph.D. Appointed Senior Vice President, Preclinical Development SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Audentes Therapeuti...
Biopharmaceuticals, Personnel
Audentes Therapeutics, gene therapy

ArtVentive Medical Receives FDA Clearance for Larger Size EOS(TM) Device

Tue, 09/29/2015 - 15:24
CARLSBAD, Calif.--(Healthcare Sales & Marketing Network)--ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its 11mm Endoluminal Occlusion System (EOS™). Desi...
Devices, Interventional, FDA
ArtVentive Medical Group, Endoluminal Occlusion System

Elekta States That Varian Claims Lack Merit

Tue, 09/29/2015 - 15:20
STOCKHOLM--(Healthcare Sales & Marketing Network)--Varian Medical Systems filed civil lawsuits and made a request that the United States International Trade Commission (USITC) initiate a patent infringement proceeding against Elekta on September 25, 2015. ...
Devices, Oncology, Litigation
Elekta, Varian Medical Systems, radiotherapy

Welch Allyn Introduces Braun ThermoScan(R) PRO 6000 Ear Thermometer that Offers Best-in-Class Thermometry Technology

Mon, 09/28/2015 - 18:28
New device accounts for variability in anatomy and technique to capture accurate, reliable readings SKANEATELES FALLS,N.Y.--(Healthcare Sales & Marketing Network)--Welch Allyn, a leading medical diagnostic device company that is now part of Hill-Rom (HR...
Devices, Product Launch
Welch Allyn, ThermoScan, Ear Thermometer

Zafgen Announces Transition of Board of Directors

Mon, 09/28/2015 - 15:17
Adds Significant Industry Leadership Experience BOSTON, Sept. 28, 2015 -- (Healthcare Sales & Marketing Network) -- Zafgen, Inc. (ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by o...
Biopharmaceuticals, Personnel
Zafgen, Beloranib, MetAP2, obesity

Teva Announces Approval of COPAXONE(R) in Japan for the Prevention of Relapse of Multiple Sclerosis

Mon, 09/28/2015 - 15:13
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) of once-daily COPAXONE® (glatiramer acetate injection...
Biopharmaceuticals, Neurology, Regulatory
Teva Pharmaceutical, COPAXONE, glatiramer, multiple sclerosis

AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

Mon, 09/28/2015 - 15:10
New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C, including those with compensated cirrhosis[1] VIEKIRAX consists of a 12-week, two direct-acting antiviral, fixed...
Biopharmaceuticals, Regulatory
AbbVie, VIEKIRAX, ombitasvir, paritaprevir, ritonavir

Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Mon, 09/28/2015 - 15:07
Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks TARRYTOWN, N.Y. and PARIS, Sept. 28, 2015 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today an...
Biopharmaceuticals, Cardiology, Regulatory
Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab, PCSK9

Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma

Fri, 09/25/2015 - 16:14
FDA orphan drug designation for avelumab an important regulatory milestone Merck-Pfizer Alliance continues to dedicate significant resources to accelerate clinical program for high-priority investigational anti-PD-L1 DARMSTADT, Germany & NEW YORK--(H...
Biopharmaceuticals, Oncology, FDA
Pfizer, Avelumab, Merkel cell carcinoma, JAVELIN Merkel 200

Elekta to Showcase New Leksell Gamma Knife Icon at Congress of Neurological Surgeons Annual Meeting

Fri, 09/25/2015 - 16:05
CNS selects Icon for its Innovations Showcase NEW ORLEANS, September 25, 2015 -- (Healthcare Sales & Marketing Network) -- Elekta's latest generation intracranial radiosurgery system, Leksell Gamma Knife® Icon™, will be in the spotlight (booth #336...
Devices, Neurosurgery
Elekta, Leksell Gamma Knife, radiosurgery, radiotherapy

Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System At CIRSE

Fri, 09/25/2015 - 13:46
Significantly increases drug delivery into liver tumors WESTMINSTER, Colo., Sept. 25, 2015 -- (Healthcare Sales & Marketing Network) -- Surefire Medical, Inc. today announced the launch of the company's new Precision targeted delivery infusion system f...
Devices, Interventional, Oncology, Product Launch
Surefire Medical, direct-to-tumor embolization, radioembolization

Celgene’s VIDAZA(R) (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia

Fri, 09/25/2015 - 13:39
Anticipated approval could provide new option for population with limited treatments Expanded indication brings medicine to elderly AML patients who are not eligible for haematopoietic stem cell transplantation and who have >30% myeloblasts in their ...
Biopharmaceuticals, Oncology, Regulatory
Celgene, Celgene International Sàrl, VIDAZA, acute myeloid leukaemia

KARL STORZ’s New FLEX-GUARD System is Designed to Reduce Repair Costs of Flexible Ureterscopes

Thu, 09/24/2015 - 16:05
New Laser Fiber and Sheath System Provides Safeguards against Mechanical & Thermal Damage EL SEGUNDO, Calif.--(Healthcare Sales & Marketing Network)--KARL STORZ Endoscopy-America, Inc., a leader in endoscopy and related technologies, is pleased to annou...
Devices, Urology, Product Launch
KARL STORZ Endoscopy, FLEX-GUARD, Ureterscope

Bovie Medical Corporation Signs GPO Agreement with Amerinet for J-Plasma

Thu, 09/24/2015 - 16:00
CLEARWATER, Fla.--(Healthcare Sales & Marketing Network)--Bovie Medical Corporation (“Bovie” or the “Company”) (BVX) a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that it has si...
Devices, Surgery, Group Purchasing, Distribution
Bovie Medical, Amerinet, J-Plasma

EU Marketing Approval Granted for VivaGel(R) BV

Thu, 09/24/2015 - 15:54
MELBOURNE, Australia--(Healthcare Sales & Marketing Network)--Starpharma (SPL.AX) (SPHRY) today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief of bacterial vaginosi...
Biopharmaceuticals, Regulatory
Starpharma, VivaGel, bacterial vaginosis

Cerulean Appoints David R. Walt, Ph.D. to Board of Directors

Thu, 09/24/2015 - 15:50
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Cerulean Pharma Inc. (Nasdaq:CERU), a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced the appointment of David R. Walt, Ph.D. to its Board of Directors, effect...
Biopharmaceuticals, Oncology, Personnel
Cerulean Pharma, Dynamic Tumor Targeting

Replimune Ltd Raises $30 Million Series A Financing

Thu, 09/24/2015 - 15:47
Atlas Venture leads Series A, joining existing seed investors Omega Funds and Forbion Capital Partners OXFORD, England, September 24, 2015 -- (Healthcare Sales & Marketing Network) --Replimune Ltd (Replimune) today announced the closing of a $30 millio...
Biopharmaceuticals, Oncology, Venture Capital

Pfizer’s Sayana(R) Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection

Thu, 09/24/2015 - 15:36
Builds on Current Momentum Towards Broadening Access to This Contraceptive Option for Women Across the Globe NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. announced today that the company’s injectable contraceptive, Sayana®Press (med...
Biopharmaceuticals, Product Launch
Pfizer, Sayana Press, medroxyprogesterone, Injectable Contraceptive

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong